ImmuneWatch strengthens its board with two proven industry leaders

ImmuneWatch has appointed Catherine Sanders and Jurgen Del Favero as external board members, reinforcing its commercial and R&D leadership as it scales its T-cell specificity platform.

To strengthen its position as a leading AI solution for T-cell specificity annotation, ImmuneWatch is adding two new external members to its board.

Catherine Sanders

Catherine is an immunopathologist with more than 20 years in biotech, spanning corporate strategy, business development, deal negotiation, sales and R&D.

She built her TCR sequencing expertise at the HudsonAlpha Institute for Biotechnology (birthplace of spin-out iRepertoire) and as VP of Research and Business Development at Adaptive Biotechnologies. As Chief Business Officer at iOrganBio today, and previously at Ozette Technologies, she brings first-hand experience scaling commercial teams in techbio ventures.

Jurgen Del Favero

Jurgen is a scientific founder and former CTO of Multiplicom, one of Belgium's most successful biotech spin-outs. His entrepreneurial track record and scientific grounding in molecular biology and cancer research make him a natural advisor for spin-off company leadership.

He currently serves as VP, Genomics Services and Innovation Strategy at CellCarta, a global leader in precision medicine testing.

Defining the T-cell specificity field

"Adding two board members with proven commercial and R&D track records is a direct investment in our strategy to define the T-cell specificity field," says Sander Wuyts, CEO of ImmuneWatch.

"Catherine spent over a decade in senior roles commercialising immune repertoire profiling. That experience will sharpen how we take our platform to market as we scale," Wuyts continues.

"Jurgen has built and scaled genomics solutions that pharma and biotech rely on for drug development decisions. He's been an early advocate for ImmuneWatch and a trusted advisor on turning academic technology into a real company," Wuyts concludes.